Lonza

The deal expands Lonza's portfolio of hematopoietic cell lines, including mobilized peripheral blood progenitor cells, for research applications.

The pharma and biotech company said it plans to use the genome editing technology in its bioproduction products and services and in stem cells for research.

The moves underscore a growing belief in industry and academia that the cell-derived vesicles could be the biomarker of choice for next-generation tests and therapies.

The Swiss biopharmaceutical company said it undertook both deals to develop new therapeutic and diagnostic applications based around exosomes.

NEW YORK (GenomeWeb News) – Precision BioSciences said today that it is suing Lonza Group and a number of its affiliates for patent infringement.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Becton Dickinson announced the latest round of winners of its BD Biosciences Research Grant Program. Winners will receive $10,000 worth of research reagents for their projects.

Lonza now offers kits and services featuring Roche's MycoTool detection kits for final release testing of pharmaceutical products, upon validation. In the meantime, Lonza continues to develop its own pharma QC products, including mycoplasma detection assays, on BD's automated testing platform.

The MycoTool PCR-based test is the first commercial nucleic acid testing-based detection system for mycoplasma biosafety testing of approved biological products.

BD Diagnostics and Switzerland's Lonza have inked an agreement to develop and commercialize Lonza's microCompass molecular assays on the BD Max system for pharmaceutical quality-control testing.

Lonza's microCompass assays will facilitate rapid detection for total bioburden load, sterility testing, Mycoplasma, and other specific organisms, the two firms said.

Pages

NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.

Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.

A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.

In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.